Lioudmila Tchistiakova's Biography

Lioudmila Tchistiakova, Senior Director, Pfizer Inc

Dr. Tchistiakova is currently Senior Director in Global Biotherapeutic Technology department at Pfizer leading development of therapeutic antibodies using rodent hybridoma approach, antibody humanization and optimization and bi-functional formats engineering. She also oversees all Oncology and CTI East coast biotherapeutic programs and focuses on optimization of antibody vehicle for antibody-drug conjugates. Prior to Pfizer, Dr. Tchistiakova worked for 8 years at Wyeth Research where she progressed from Principal Scientist III to Director level by leading generation of biotherapeutics on more than 15 programs in collaboration with Inflammation, Neuroscience, CMVD and Oncology, seven of these projects progressed to clinical development including anti-myostatin mAb RK35, anti-IL-13 mAb IMA-638, anti-A-beta mAb AAB-03, 5T4 ADC and Notch3ADC. Dr Tchistiakova also held the position of Section Head at Albany Molecular Research Inc., where she led internal and collaborative Drug Screening Programs using company`s natural product libraries and was also one of the co-founders of Supratek Pharma Inc. in Montreal, Canada where she held Senior Scientist and Group Leader positions from 1995 to 2001 and was responsible for targeted drug delivery efforts. Dr. Tchistiakova received her Ph.D. degree in Biochemistry from the Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. Dr. Tchistiakova has coauthored of over 50 scientific publications, book chapters and patents.